Human Lipocalin-2  ELISA Kit

Human Lipocalin-2 ELISA Kit

SKU: 31050

★ Download Datasheet PDF 

★ Download MSDS ★

 

Assay range: 0.39 – 25 ng/mL

Kit Size: 96 wells/kit

Other Names: LCN2, NGAL, neutrophil lipocalin (NL), 24p3, siderocalin, MSFI

  • INTRODUCTION

    Lipocalin-2, also known as neutrophil gelatinase-associated lipocalin (NGAL), 24p3, siderocalin, or neutrophil lipocalin (NL), is a secretory glycoprotein expressed in liver, lung, kidney, adipocytes, activated neutrophils and macrophages.
    Lipocalin-2 is upregulated under various inflammation and infection conditions and can be served as a sensitive biomarker for various renal injuries. Serum levels of lipocalin-2 are positively correlated with obesity, insulin resistance, hyperglycemia, coronary heart disease and fatty liver disease in humans.

  • PRINCIPLE OF THE ASSAY

    This assay is a quantitative sandwich ELISA using monoclonal antibodies against human LCN2. The immunoplate is pre-coated with a monoclonal antibody specific for human LCN2. Standards and samples are added into the wells and any human LCN2 present is captured by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidase (HRP)-linked monoclonal antibody specific for human LCN2 is added to the wells. After a final washing step to remove any unbound reagents, a HRP substrate solution is added and colour develops in proportion to the amount of human LCN2 bound initially. The reaction is stopped and the optical density of the wells determined using a microplate reader. Since the increases in absorbance are directly proportional to the amount of captured human LCN2, the unknown sample concentration can be interpolated from a reference curve included in each assay.

  • ASSAY PERFORMANCE

    A. Typical representation of standard curve

    The following standard curve is provided for demonstration only. A standard curve should be generated for each set of sample assay.

    Human lipocalin-2 (ng/mL)

    Absorbance (450 nm)

    Blanked Absorbance

    0

    0.076

    0

    0.39

    0.107

    0.031

    0.78

    0.137

    0.061

    1.56

    0.203

    0.127

    3.12

    0.343

    0.267

    6.25

    0.647

    0.571

    12.5

    1.26

    1.184

    25

    2.492

    2.416

     

    B. Sensitivity

    The lowest level of lipocalin-2 that can be detected by this assay is 0.39 ng/mL.

     

    C. Specificity

    The antibody pair used in this assay is specific to human lipocalin-2 and does not cross-react with mouse and rat lipocalin-2, and other cytokine or hormone molecules.

  • PUBLICATIONS CITING THIS PRODUCT

    1. Alkharfy KM, Al-Daghri NM, Vanhoutte PM, Krishnaswamy S, Xu A. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PloS one. 2012 Oct 31;7(10):e48612.
    2. Xiao Y, Xu A, Hui X, Zhou P, Li X, Zhong H, Tang W, Huang G, Zhou Z. Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. PLoS One. 2013 Jun 17;8(6):e66607.
    3. Heilbronn LK, Campbell LV, Xu A, Samocha-Bonet D. Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PloS one. 2013 Oct 18;8(10):e78864.
    4. Ni J, Ma X, Zhou M, Pan X, Tang J, Hao Y, Lu Z, Gao M, Bao Y, Jia W. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovascular diabetology. 2013 Dec;12(1):1-7.
    5. Wu G, Li H, Fang Q, Jiang S, Zhang L, Zhang J, Hou X, Lu J, Bao Y, Xu A, Jia W. Elevated circulating lipocalin-2 levels independently predict incident cardiovascular events in men in a population-based cohort. Arteriosclerosis, thrombosis, and vascular biology. 2014 Nov;34(11):2457-64.
    6. Chen DL, Liess C, Poljak A, Xu A, Zhang J, Thoma C, Trenell M, Milner B, Jenkins AB, Chisholm DJ, Samocha-Bonet D. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. The Journal of Clinical Endocrinology & Metabolism. 2015 Nov 1;100(11):4082-91.
    7. Na GY, Yoon SR, An J, Yeo R, Song J, Jo MN, Han S, Kim OY. The relationship between circulating neutrophil gelatinase-associated lipocalin and early alteration of metabolic parameters is associated with dietary saturated fat intake in non-diabetic Korean women. Endocrine journal. 2016:EJ16-0233.
    8. Luo Y, Ma X, Pan X, Xu Y, Xiong Q, Xiao Y, Bao Y, Jia W. Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men. Medicine. 2016 Jul;95(30).
    9. Chen DL, Brown R, Liess C, Poljak A, Xu A, Zhang J, Trenell M, Jenkins A, Chisholm D, Samocha-Bonet D, Macefield VG. Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men. Frontiers in physiology. 2017 Feb 28;8:101.
    10. Yang K, Deng HB, Man AW, Song E, Zhang J, Luo C, Cheung BM, Yuen KY, Jensen PS, Irmukhamedov A, Elie AG. Measuring non‐polyaminated lipocalin‐2 for cardiometabolic risk assessment. ESC heart failure. 2017 Nov;4(4):563-75.
    11. Sun WY, Bai B, Luo C, Yang K, Li D, Wu D, Félétou M, Villeneuve N, Zhou Y, Yang J, Xu A. Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury. JCI insight. 2018 Sep 6;3(17).
    12. Wong YK, Cheung CY, Tang CS, Au KW, Hai JS, Lee CH, Lau KK, Cheung BM, Sham PC, Xu A, Lam KS. Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2018 Oct;38(10):2519-27.
    13. Elie AG, Bloksgaard M, Sun WY, Yang K, Man AW, Xu A, Irmukhamedov A, Riber LP, Wang Y, De Mey JG. Local enrichment of fatty acid-binding protein 4 in the pericardial cavity of cardiovascular disease patients. PloS one. 2018 Nov 5;13(11):e0206802.
    14. Xu Y, Ma X, Pan X, He X, Xiao Y, Bao Y. Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women. Cardiovascular diabetology. 2018 Dec;17(1):1-9.
    15. Xiao Y, Xiao X, Xu A, Chen X, Tang W, Zhou Z. Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes. Journal of Diabetes and its Complications. 2018 Dec 1;32(12):1100-4.
    16. Tang A, Coster AC, Tonks KT, Heilbronn LK, Pocock N, Purtell L, Govendir M, Blythe J, Zhang J, Xu A, Chisholm DJ. Longitudinal changes in insulin resistance in normal weight, overweight and obese individuals. Journal of clinical medicine. 2019 May;8(5):623.
    17. Wu L, Qian L, Zhang L, Zhang J, Zhou J, Li Y, Hou X, Fang Q, Li H, Jia W. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. Journal of the American Heart Association. 2020 Jun 2;9(11):e015226.
    18. Harari A, Coster AC, Jenkins A, Xu A, Greenfield JR, Harats D, Shaish A, Samocha-Bonet D. Obesity and insulin resistance are inversely associated with serum and adipose tissue carotenoid concentrations in adults. The Journal of nutrition. 2020 Jan 1;150(1):38-46.
    19. Ong KL, Wu L, Januszewski AS, O'Connell RL, Xu A, Rye KA, Ma RC, Li H, Jenkins AJ, Jia W, Keech AC. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice. 2020 Nov 1;169:108450.
$370.00Price

For bulk order (QTY: 5 or more), please contact us for quote